Types of Blood and Marrow Stem Cell Transplants
John Theurer Cancer Center performs all types of blood and marrow stem cell transplants, including:
- Allogeneic – stem cells from a donor
- Autologous – stem cells from the patient
We offer special expertise in:
- Bloodless (no transfusion) for autologous transplants
- Matched and mismatched transplants from unrelated donors
- Partial match (haploidentical) transplant – stem cells from someone who partially matches you
- Umbilical cord blood transplants
Expertise in Photopheresis
One of the biggest challenges with stem cell transplant is the risk of graft-versus-host disease, a complication in which immune cells from the donor attack normal tissue of the recipient.
John Theurer Cancer Center offers expertise in a therapy called photopheresis to treat graft-versus-host disease. We remove some of your white blood cells, treat them with a medication called methoxsalen and then expose them to ultraviolet light. Once returned to your bloodstream, these supercharged white blood cells help your immune system fight graft-versus-host disease.
Your Team of Experts
Your blood and marrow stem cell transplant team features doctors with decades of experience, including specialists who focus specifically on leukemia, lymphoma and multiple myeloma. The teams meet weekly to develop treatment plans for each patient.
Our advanced practice nurses, case managers, nurse navigators, social workers, pharmacists and registered dieticians all specialize in the care of transplant patients. In fact, many of our nurses have certification in oncology and stem cell transplantation.
Our Research and Clinical Trials
At John Theurer Cancer Center, you may have the opportunity to participate in a clinical trial of new and exciting approaches to stem cell transplant. Our research has a strong focus on reducing the complications of transplant and also lowering the risk of disease recurrence. We are the first in the world to combine checkpoint inhibitors (drugs that inhibit the proteins cancer cells use to evade detection by the immune system) after transplantation, at a time when the immune system has the best opportunity to eliminate any remaining cancer cells.
Current Clinical Trials
